Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 21, 2012

Novartis Pays Enanta $34M Up Front for Worldwide Rights to HCV NS5A Inhibitors

  • Novartis is paying Enanta Pharmaceuticals $34 million up front for worldwide rights to develop and commercialize the latter’s lead HCV NS5A inhibitor candidate, EDP-239. Enanta could receive up to $406 million in clinical, regulatory, and commercial milestones plus tiered double-digit royalties on sales and retains co-detail rights in the U.S.

    Under terms of the deal Novartis will shoulder all costs associated with the development, manufacture, and commercialization of EDP-239. It will also provide Enanta with funding for the discovery of additional compounds targeting NS5A.

    NS5A is a nonstructural viral protein that is critical for viral replication. Enanta says its EDP-239 inhibitor has demonstrated high potency against multiple HCV genotypes in vitro, and its preclinical pharmacokinetic profile supports the potential for once-daily dosing in humans.

    Anti-infectives specialist Enanta is developing HCV protease, polymerase, and cyclophilin-based inhibitors and has generated a class of macrolide antibiotics, called bicyclolides, which it claims can overcome bacterial resistance. The firm teamed up with Abbott in 2006 to develop and commercialize HCV HS3 and NS3/4A protease inhibitors through a $57 million cash and equity investment deal that also gives its partner access to drug discovery capabilities in the field of HCV NS3 and NS3/4A protease inhibitor field. Enanta’s HCV polymerase and cyclophilin programs are ongoing in house.

    Enanta’s bicyclolide program is focused on the development of oral broad-spectrum candidates against community MRSA and community-acquired respiratory tract infections caused by pathogens including S. pneumonia, S. aureus, S. pyogenes, and H. influenza as well as a hospital-acquired MRSA and VRE.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »